GLPG0634 clinical trials
Also written Filgotinib, GLPG0634 and GS-6034.
How each study uses GLPG0634 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GLPG0634 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 24 Sept 2020 · Jyseleca · EMEA/H/C/005113 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2017 (13)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 4 |
| 2016 | 5 |
| 2017 | 13 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 44 · Other 6
Galapagos NV (19) · Gilead Sciences (16) · Alfasigma S.p.A. (7) · Lakefront Biotherapeutics NV (2) · Leiden University Medical Center (1) · University Hospital, Toulouse (1) · UMC Utrecht (1) · R.Bos (1)
Often tested with
Tested in the same studies.
Lanraplenib (3) · Methotrexate (1) · Tirabrutinib (1) · Baricitinib (1) · Tofacitinib (1) · Upadacitinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test GLPG0634, phase 3 first.
- Jun 2027Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and AdolescentsPhase 3 · Alfasigma S.p.A.
- Dec 2026Drug Rediscovery for Rare Immune Mediated Inflammatory DiseasesPhase 2 · UMC Utrecht
Studies
Open first, then newest update. How each study uses GLPG0634 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative ColitisRecruitingPhase 3Alfasigma S.p.A.NCT06865417Written as Filgotinib
- OLE Study With Filgotinib in JIARecruitingPhase 3Alfasigma S.p.A.NCT07553182Written as Filgotinib
- JAK Inhibitor Dose TAPering Strategy StudyRecruitingPhase 4University Hospital, ToulouseNCT06687551Written as filgotinib 200mg/day
- Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and AdolescentsRecruitingPhase 3Alfasigma S.p.A.NCT07554495Written as Filgotinib
- Drug Rediscovery for Rare Immune Mediated Inflammatory DiseasesRecruitingPhase 2UMC UtrechtNCT06285539Written as Filgotinib
- Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)RecruitingPhase 4R.BosNCT04985435Written as Filgotinib
- Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)RecruitingPhase 4Universita di VeronaNCT06527534Written as Filgotinib
- Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid ArthritisNot yet recruitingPhase 4Leiden University Medical CenterNCT05502731Written as Filgotinib
- Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisCompletedPhase 3Alfasigma S.p.A.NCT02914535Written as Filgotinib
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisCompletedPhase 3Alfasigma S.p.A.NCT03025308Written as Filgotinib
- Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)TerminatedPhase 1Alfasigma S.p.A.NCT06222034Written as Filgotinib
- A Study Evaluating the Effect of Filgotinib in Participants With Active Axial SpondyloarthritisActive, not recruitingPhase 3Alfasigma S.p.A.NCT05785611Written as Filgotinib
- Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseTerminatedPhase 2Lakefront Biotherapeutics NVNCT03201445Written as Filgotinib
- A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionTerminatedPhase 3Galapagos NVNCT05479058Written as Filgotinib
- Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseTerminatedPhase 3Galapagos NVNCT02914600Written as Filgotinib
- Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsCompletedPhase 2Galapagos NVNCT02065700Written as Filgotinib
- Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisCompletedPhase 2Galapagos NVNCT03926195Written as Filgotinib
- Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseCompletedPhase 3Lakefront Biotherapeutics NVNCT02914561Written as Filgotinib
- Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy SubjectsCompletedPhase 1Galapagos NVNCT06043739Written as Filgotinib
- Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsCompletedPhase 1Gilead SciencesNCT04608344Written as Filgotinib
See all 50 studies that test GLPG0634 →
Given beside what is tested · 1 — GLPG0634 is usual care or a partner of the new treatment
Codes
What other systems call GLPG0634 · ClinicalTrials.gg INT006381
- MeSH (NLM) C584571GLPG0634One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584571 | GLPG0634 | One source ClinicalTrials.gov |
Also registered as filgotinib (UNII 3XVL385Q0M) and filgotinib hydrochloride (UNII 2CQ8Y0B8XQ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.